1-[氯(二苯基)甲基]-2-氟苯 | 379-40-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 1-[氯(二苯基)甲基]-2-氟苯
• 英文名称: diphenyl-ortho-fluorophenyl-methylchloride
• 英文别名: 2-fluoro-trityl chloride；2-Fluor-tritylchlorid；chloro-(2-fluorophenyl)-diphenylmethane；1-(Chlorodiphenylmethyl)-2-fluorobenzene；1-[chloro(diphenyl)methyl]-2-fluorobenzene
• CAS: 379-40-8
• 化学式: C₁₉H₁₄ClF
• 分子量: 296.772
• InChiKey: DNPUOCDJCMLJRY-UHFFFAOYSA-N

物化性质

• 熔点：
  109-110 °C
• 沸点：
  396.1±37.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-[氯(二苯基)甲基]-2-氟苯 以 甲苯 为溶剂， 生成 2-(2-fluorophenyl)-2,2-diphenylacetonitrile
  参考文献：
  名称：

  Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease

  摘要：

  本发明提供了一类化合物，可用作治疗镰状细胞病和以不需要或异常细胞增殖为特征的疾病的有效药物，特别是与不需要的细胞增殖相关的炎症性疾病。这些活性化合物是取代的三芳基甲烷化合物或其类似物，其中芳基之一或多个被取代为杂芳基、环烷基或杂环烷基，以及/或者第三级碳原子被其他原子如硅、锗、氮或磷所取代，这些化合物抑制哺乳动物细胞增殖，抑制红细胞的Gardos通道，减少镰状红细胞的脱水，和/或延迟红细胞的镰刀形成或变形的发生。

  公开号：

  US06331564B1
• 作为产物：
  描述：

  邻氟苯甲酸甲酯 在 乙酰氯 作用下， 以 乙醚 、 苯 为溶剂， 反应 1.67h， 生成 1-[氯(二苯基)甲基]-2-氟苯
  参考文献：
  名称：

  带有ω-氟化侧基的环戊二烯基和茚基配体的合成和反应性。(ortho-F-C6H4)-CPh2-C5H4SiMe3 的晶体结构

  摘要：

  已经合成了一系列带有 ω-氟化侧基的环戊二烯和茚，并研究了它们对金属化剂 n-BuLi、NaH、TlOEt、Me3SiCl、Me3SnCl、TiHal4、ZrX4（X = Cl、NMe2）的反应性。确定了1-三甲基甲硅烷基-3-(二苯基-邻-氟苯基-甲基)-环戊二烯(3)的晶体结构。

  DOI：

  10.1515/znb-2002-1104

文献信息

• Triaryl methane compounds and analogues thereof useful for the treatment
  申请人：Children's Medical Center Corporation

  公开号：US06028103A1

  公开（公告）日：2000-02-22

  The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

  本发明提供了一类化合物，可作为治疗镰状细胞病和以不需要或异常细胞增殖为特征的疾病的有效药物。这些活性化合物是取代的三芳基甲烷化合物或其类似物，其中芳基中的一个或多个被取代为杂芳基、环烷基或杂环烷基，或者第三级碳原子被硅、锗、氮或磷等不同的原子取代。这些化合物抑制哺乳动物细胞的增殖，抑制红细胞的Gardos通道，减少镰状红细胞的脱水，延迟红细胞的镰刀变形或变形的发生。
• Organizational Buying and Advertising Agency-Client Relationships in China
  作者：Gerard Prendergast、Yizheng Shi、Douglas West

  DOI：10.1080/00913367.2001.10673638

  日期：2001.6

  The 1980s and 1990s have seen the development of an interesting, diverse, and relevant body of literature on the advertising agency-client relationship. In recent times, an area of focus has been the application of organizational buying behavior principles to companies that are purchasing advertising services from advertising agencies. However, little is known about the application of such theories in the context of a developing country. After examining the literature relating to China's advertising industry and the application of organizational buying behavior principles in the advertising industry, this article reports on a survey of 200 firms in Shanghai. The results unexpectedly show that advertising agency power in the campaign development process is not related to the nature of the advertising task (new task, modified rebuy, straight rebuy) at hand. In addition, bottom-up processes give agencies the weakest pourer, and the client buying process is dominated by marketers, the salesforce, and public relations, with top managers the primary deciders.
• Bartroli; Alguero; Boncompte, Arzneimittel-Forschung/Drug Research, 1992, vol. 42, # 6, p. 832 - 835
  作者：Bartroli、Alguero、Boncompte、Forn

  DOI：——

  日期：——
• Bergmann, Recueil des Travaux Chimiques des Pays-Bas, 1939, vol. 58, p. 863,869
  作者：Bergmann

  DOI：——

  日期：——
• Novel Inhibitors of the Gardos Channel for the Treatment of Sickle Cell Disease
  作者：Grant A. McNaughton-Smith、J. Ford Burns、Jonathan W. Stocker、Gregory C. Rigdon、Christopher Creech、Susan Arrington、Tara Shelton、Lucia de Franceschi

  DOI：10.1021/jm070663s

  日期：2008.2.1

  Sickle cell disease (SCD) is a hereditary condition characterized by deformation of red blood cells (RBCs). This phenomenon is due to the presence of abnormal hemoglobin that polymerizes upon deoxygenation. This effect is exacerbated when dehydrated RBCs experience a loss of both water and potassium salts. One critical pathway for the regulation of potassium efflux from RBCs is the Gardos channel, a calcium-activated potassium channel. This paper describes the synthesis and biological evaluation of a series of potent inhibitors of the Gardos channel. The goal was to identify compounds that were potent and selective inhibitors of the channel but had improved pharmacokinetic properties compared to 1, Clotrimazole. Several triarylamides such as 10 and 21 were potent inhibitors of the Gardos channel (IC50 of < 10 nM) and active in a mouse model of SCD. Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.